Scorr-Insert
X

Find Drugs for Infections and Infectious Diseases in Phase I/ Phase II Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BNT162

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 05, 2020

            Details:

            The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates, under BNT162 vaccine program, evaluated in a single, continuous study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX?CoV2373

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 25, 2020

            Details:

            Novavax is developing a “subunit” vaccine - which sends copies of the virus’s spike protein directly into the body to stimulate an immune response.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rintatolimod,Interferon Alfa-2B

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 14, 2020

            Details:

            The new clinical trial to be conducted will test the safety of Ampligen (rintatolimod), in combination with interferon alfa-2b in patients with cancer and mild to moderate COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: $388.0 million Upfront Cash: Undisclosed

            Deal Type: Funding May 11, 2020

            Details:

            CEPI funding will boost clinical development of NVX-CoV2373 through Phase 2 and also, it supports rapid scale-up of vaccine manufacturing.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Shigella bacteriophage therapy

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: NIAID

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding May 04, 2020

            Details:

            This NIAID-funded project will assess the safety and efficacy of the Shigella bacteriophage preparation developed by Intralytix in Phase 1/2a clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VIR-2218

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2020

            Details:

            Significant dose-dependent and durable reduction in hepatitis B surface antigen through Week 24 in patients with chronic HBV who received two doses of VIR-2218, ranging from 20 mg to 200 mg.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ranpirnase

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Orgenesis

            Deal Size: $19.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition April 14, 2020

            Details:

            Orgenesis and TamirBio plan to combine ranpirnase with Bioxomes, which have shown the ability to fuse with cell membranes and deliver an intracellular cargo, in a similar manner to natural exosomes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Jenner Institute

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 14, 2020

            Details:

            Merck supported the Jenner team and their collaborators to evaluate the existing manufacturing platform for use with the new vaccine candidate, and improved critical process steps.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AP-PA02

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Innoviva

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Financing March 30, 2020

            Details:

            The completion of $25 million financing with Innoviva provides Armata with significant resources that will allow it to efficiently advance its pipeline of phage-based therapeutics.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AP-PA02

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Funding March 18, 2020

            Details:

            The award will help fund a Phase 1/2 clinical trial of the company's Pseudomonas aeruginosa phage candidate, AP-PA02, as a treatment for Pseudomonas airway infections in people with cystic fibrosis.

            PharmaCompass